As previously disclosed, the new subsidiary will be located in Wuxi, a growth area just outside Shanghai. The corporate office will be located at I•Campus, Astra Zeneca’s life science startup hub; this opens opportunities for cooperation with other, similar companies and local organizations with experience of registration of foreign products in China.

Together with the consultancy firm Nordic Match, Calmark has now also prepared an information memorandum (IM) for the planned joint venture. Discussions with interested Chinese investors are underway. 

"We are exceedingly happy about the constructive cooperation with Nordic Match", says Anna Söderlund, CEO of Calmark. "Their solid experience of cross-border transactions between China and the Nordic countries, entrepreneurial mindset and great passion for business are most valuable to us at this stage."

 

For more information about Calmark Sweden AB, please contact:

Anna Söderlund, CEO
Telefon: +46 70 214 98 93
E-post: anna.soderlund@calmark.se 
www.calmark.se 

Calmark Sweden AB is a medical technology company developing a point-of-care (POC) analysis method with easier and faster diagnostics of medical conditions in newborns. The unique test platform consists of a portable instrument and test cassettes for various biomarkers. The first test, Neo-Bilirubin, was launched to the market in 2020. In the Western world, the introduction of POC diagnostics is resulting in huge savings and shorter care chains. In less developed healthcare systems, the product will offer a decision support which is currently lacking, since the access to hospital laboratories often is limited. Calmark aims to become the global leader in POC diagnostics for newborns and, in the long term, to offer all relevant tests for the first period of life. In addition to products for newborns, Calmark develops a POC test for assessment of COVID-19 disease severity. The B share is listed on the Spotlight Stock Market and is traded under the CALMA B ticker. Read more at www.calmark.se/eng/home.